Get the Stockscreener App
30.94
4.53%
1.34
Oruka Therapeutics Inc stock is traded at $30.94, with a volume of 342.21K.
It is up +4.53% in the last 24 hours and up +12.80% over the past month.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$29.60
Open:
$29.5
24h Volume:
342.21K
Relative Volume:
0.77
Market Cap:
$1.50B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.58%
1M Performance:
+12.80%
6M Performance:
+164.90%
1Y Performance:
+47.54%
1-Day Range:
$29.04
$31.21
1-Week Range:
$26.73
$31.21
52-Week Range:
$5.485
$31.21
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
30.94 | 1.43B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Jefferies | Buy |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Can Oruka Therapeutics Inc. stock deliver consistent earnings growthCEO Change & AI Based Buy and Sell Signals - Newser
Will Oruka Therapeutics Inc. stock sustain high P E ratios2025 Volatility Report & Safe Capital Growth Plans - Newser
Is Oruka Therapeutics Inc. (HQ1) stock dividend growth reliable2025 Risk Factors & Consistent Profit Trading Strategies - Newser
Oruka Therapeutics stock hits 52-week high, reaching $31.01 - Investing.com
Oruka Therapeutics stock hits 52-week high, reaching $31.01 By Investing.com - Investing.com India
Should I hold or sell Oruka Therapeutics Inc. stock in 2025Market Movement Recap & AI Based Buy and Sell Signals - Newser
Is Oruka Therapeutics Inc. (HQ1) stock undervalued at current priceJuly 2025 Snapshot & Community Verified Trade Alerts - Newser
Is Oruka Therapeutics Inc. (HQ1) stock a momentum leaderQuarterly Portfolio Review & Long-Term Safe Investment Plans - Newser
Will Oruka Therapeutics Inc. stock see insider buyingMarket Growth Review & Consistent Profit Trading Strategies - Newser
How Oruka Therapeutics Inc. (HQ1) stock performs during market turbulence2025 Dividend Review & Breakout Confirmation Trade Signals - Newser
What valuation ratios show for Oruka Therapeutics Inc. (HQ1) stock2025 Support & Resistance & Reliable Breakout Forecasts - Newser
Will Oruka Therapeutics Inc. (HQ1) stock hit analyst forecastsWeekly Profit Analysis & Breakout Confirmation Alerts - Newser
Franklin Resources Inc. Purchases 292,421 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
ORKA-001 Advances Toward Yearly Dosing - Dermatology Times
How Investors Are Reacting To Oruka Therapeutics (ORKA) Once-Yearly Psoriasis Treatment Breakthrough - sahmcapital.com
What drives Oruka Therapeutics Inc stock priceSupport Zone Identification & Rapid Capital Growth - earlytimes.in
Its Stock Has Paid Off Big Time For Oruka Therapeutics Inc - Setenews
Oruka Therapeutics stock hits 52-week high at 30.29 USD By Investing.com - Investing.com Australia
Oruka Therapeutics stock hits 52-week high at 30.29 USD - Investing.com
Does Oruka Therapeutics Inc. stock trade at a discount to peersJuly 2025 Volume & Weekly Market Pulse Alerts - newser.com
Jefferies Sticks to Its Buy Rating for Oruka Therapeutics (ORKA) - The Globe and Mail
Can Oruka Therapeutics Inc. (HQ1) stock hit consensus price targetsWeekly Trade Review & Capital Protection Trading Alerts - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock rise with strong economyRate Cut & High Accuracy Trade Signal Alerts - newser.com
Is Oruka Therapeutics Inc. stock attractive for income investorsQuarterly Investment Review & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-19 21:53:09 - newser.com
Can Oruka Therapeutics Inc. (HQ1) stock surprise with quarterly resultsPortfolio Profit Report & Long Hold Capital Preservation Tips - newser.com
Can Oruka Therapeutics Inc. stock sustain market leadershipEarnings Trend Report & Weekly Breakout Watchlists - newser.com
Published on: 2025-11-19 17:15:05 - newser.com
Key metrics from Oruka Therapeutics Inc.’s quarterly dataPortfolio Gains Summary & Fast Gain Swing Trade Alerts - newser.com
Can momentum traders help lift Oruka Therapeutics Inc.July 2025 Closing Moves & Reliable Volume Spike Trade Alerts - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock sustain dividend payoutsWeekly Stock Summary & Proven Capital Preservation Methods - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock attract long term capital inflowsDividend Hike & Safe Capital Growth Tips - newser.com
Why Oruka Therapeutics Inc. (HQ1) stock is trending on social mediaQuarterly Market Summary & Free High Return Stock Watch Alerts - newser.com
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):